Tolerability and Efficacy of Tremelimumab in Combination With Gefitinib in NSCLC Patients

NCT02040064 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

27

Enrollment

OTHER

Sponsor class

Conditions

Non Small Cell Lung Cancer

Interventions

DRUG: Gefitinib
DRUG: Tremelimumab

Sponsor

Gustave Roussy, Cancer Campus, Grand Paris

Collaborators

[object Object]